top of page

October 2021 // Company

Synendos Therapeutics Appoints Scientific Advisory Board

Synendos Therapeutics is thrilled to announce the formation of the Scientific Advisory Board composed of prominent scientists and clinicians with significant CNS expertise.

Download here below the full press release.

Synendos Press Release October 2021
Download PDF • 249KB

Recent Posts

See All

January 2024 // Company & Communication

Synendos granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510. Synendos transitions to a clinical-stage biotech company developing innovative Endocanna

October 2022 // Company

Synendos Therapeutics has been awarded with the Innosuisse Certificate Synendos has been awarded the Innosuisse certificate by Innosuisse Innovation Council. The Innosuisse certificate reflects remark

September 2022 // Company & Communication

Synendos Therapeutics is ranked TOP 100 Swiss Startups 2022 We are honored to be listed for the second year in a row as one of the TOP 100 Swiss Startups 2022. A big thank you to our team, partners, c


bottom of page